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S U M M A R Y
Introduction: Platelets are under investigation for their role in host defence and inflammatory lung diseases and
have been demonstrated to be recruited to the lung. However, the mechanisms and consequences of platelet
recruitment into lungs are poorly understood. We have utilised a murine model to investigate the mechanisms of
platelet involvement in lung inflammation induced by intranasal administration of LPS.
Objectives: Our aim was to characterise lung platelet recruitment following LPS inhalation in mice using im-
munohistochemistry, and non-invasive and invasive radiolabelled platelet tracking techniques.
Results: Intranasal administration of LPS caused an increase in lung platelet staining in lung tissue and elicited
the recruitment of radiolabelled platelets into the lung. Prior to these responses in the lung, we observed an
earlier decrease in blood platelet counts, temporally associated with platelet recruitment to the liver and spleen.
Non-invasive measurements of thoracic radioactivity reflected changes in blood counts rather than extravascular
lung platelet recruitment. However, both in situ counting of radiolabelled platelets and immunostaining for
platelet surface markers showed LPS-induced increases in extravascular platelets into lung airspaces suggesting
that some of the platelets recruited to the lung enter air spaces.
Conclusions: Intranasal administration of LPS activates the innate immune response which includes a fall in
peripheral blood platelet counts with subsequent platelet recruitment to the lung, spleen and liver, measured by
immunohistochemistry and radiolabelling techniques.
1. Introduction
Platelets make important contributions to haemostasis, thrombosis,
inflammation and regeneration, and drugs targeting platelets have
garnered interest as potential anti-inflammatory interventions for the
treatment of inflammatory lung diseases (Amison, Arnold,
O'Shaughnessy, et al., 2017; Amison, Momi, Morris, et al., 2015; Li,
Zarbock, & Hidalgo, 2017; Middleton, Weyrich, & Zimmerman, 2016;
Nachman & Weksler, 1972; Page, 1988; Pitchford, 2006; Semple,
Italiano, & Freedman, 2011; Weyrich & Zimmerman, 2013). Observa-
tional clinical studies are suggestive of increased survival of patients
with chronic obstructive pulmonary disease (COPD) or the acute re-
spiratory distress syndrome (ARDS) receiving anti-platelet treatment
(Ekström, Hermansson, & Ström, 2013; Pavasini et al., 2016; Toner,
McAuley, & Shyamsundar, 2015). Studies in experimental animals have
shown that inflammatory responses depend on platelets in models of
allergic airway inflammation (Chae et al., 2016; Pitchford et al., 2003;
Pitchford et al., 2004; Pitchford et al., 2005), LPS-induced lung in-
flammation (Grommes et al., 2012; Kornerup, Salmon, Pitchford, Liu, &
Page, 2010), other sterile lung injury models (Looney et al., 2009;
Zarbock, Singbartl, & Ley, 2006), and following respiratory infection
(Amison, O'Shaughnessy, Arnold, et al., 2018). Furthermore, clinical
trials with human volunteers exposed to LPS to assess the potential of
anti-platelet drugs to have anti-inflammatory activity, have shown re-
ductions in inflammation following treatment with the anti-platelet
drugs clopidogrel, ticagrelor or aspirin (Hamid et al., 2017; Thomas
et al., 2015). However, interventional studies carried out so far using
existing anti-platelet drugs in more complex clinical settings, for ex-
ample using aspirin for prevention of ARDS (Kor et al., 2016), and
prasugrel to treat allergic asthma (Lussana et al., 2015), have not found
clear beneficial effects demonstrating a need for better understanding of
how and when to target platelets in the context of inflammatory lung
https://doi.org/10.1016/j.vascn.2019.106660
Received 1 July 2019; Received in revised form 21 October 2019; Accepted 1 December 2019
⁎ Corresponding author.
E-mail address: simon.pitchford@kcl.ac.uk (S.C. Pitchford).
Journal of Pharmacological and Toxicological Methods 102 (2020) 106660
Available online 12 December 2019
1056-8719/ © 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license 
(http://creativecommons.org/licenses/BY/4.0/).
T
diseases.
Many functions of platelets depend on juxtacrine and paracrine
signalling which necessitate platelet adhesion on exposed sub-
endothelial tissue, endothelium or endothelium-adhesive leukocytes or
other platelets (Middleton et al., 2016). Platelet recruitment into lungs
has been suggested to be a pathological response occurring in a variety
of inflammatory states, including following LPS challenge in guinea
pigs (Beijer et al., 1987), rats (Itoh, Cicala, Douglas, & Page, 1996),
rabbits (Kiefmann et al., 2004), and mice (Ortiz-Muñoz et al., 2014).
Platelets have also been suggested to migrate out of the bloodstream
and into tissue and airspaces in inflamed lungs in mouse models of
allergic airway inflammation (Pitchford et al., 2008) and following LPS
inhalation (Ortiz-Muñoz et al., 2014; Rylander, Beijer, Lantz, Burrell, &
Sedivy, 1988), a phenomenon with poorly understood mechanisms and
consequences.
Although LPS inhalation has been previously been suggested to
cause platelet recruitment to the lungs and lung airspaces of guinea pigs
(Beijer et al., 1987; Rylander et al., 1988), lung platelet recruitment
following LPS inhalation has not yet been assessed by visualisation of
platelets in lung tissues.
We have therefore utilised a mouse model of LPS inhalation similar
to those previously suggested to cause platelet-dependent lung neu-
trophil recruitment (Kornerup et al., 2010), and platelet recruitment
and platelet migration into airspaces (Ortiz-Muñoz et al., 2014). The
effect of LPS inhalation via intranasal administration on platelet con-
tent of lungs was assessed in this model using immunohistochemical
staining of CD41 (ITGA2B, αIIb), and using a well-established non-in-
vasive method for tracking radiolabelled platelets (Page, Paul, &
Morley, 1982) previously used for measuring pulmonary thromboem-
bolism in mice (Tymvios et al., 2008), as well as radiolabelled platelet
biodistribution methods similar to those used in inflammation models
(Andonegui et al., 2005; Looney et al., 2009).
2. Methods
2.1. Animals
Female BALB/c mice were purchased from Charles River and used at
6–12 weeks of age. Experiments were approved by King's College
London Ethics committee and carried out in accordance with the UK
Animals (Scientific Procedures) Act 1986 and EU directive 2010/63/
EU. Animal studies are reported in accordance with the ARRIVE
guidelines (Kilkenny, Browne, Cuthill, Emerson, & Altman, 2010).
2.2. Intranasal LPS challenge model
Mice were briefly anaesthetised with isoflurane, then challenged via
the intranasal route with LPS (O55:B5 from E. coli, 5 mg/kg, 2 μl/g), a
dose based on previous reports Ortiz-Muñoz et al. (2014) or PBS ve-
hicle, before recovery. This method has previously been shown to de-
posit ~55% of the delivered dose of LPS in the lungs (Southam,
Dolovich, O'Byrne, & Inman, 2002; Su, Looney, Robriquet, Fang, &
Matthay, 2004). The terminal anaesthetic used was urethane (3 g/
kg i.p. in PBS), given at a time point when neutrophils are detectable in
airspaces (+4 h)or at a time point when lung platelet recruitment into
lungs has previously been demonstrated (+48 h) (Cleary et al., 2019;
Ortiz-Muñoz et al., 2014).
2.3. Buffer solutions
PBS (137 mM NaCl, 3 mM KCl, 8 mM Na2HPO4 and 1.5 mM
KH2PO4, pH 7.3) was made up from tablets (Oxoid). DAB development
buffer was made up immediately before use with 1.2 mM DAB (3,3-
diaminobenzidine tetrahydrochloride) in 0.1 M Tris buffer (pH 7.6) and
0.03% vol/vol H2O2 substrate. Acid-citrate dextrose (ACD) antic-
oagulant was from Sigma-Aldrich. Calcium and Magnesium-free
Tyrode's solution (CFTS) was 134 mM NaCl, 2.7 mM KCl, 5.55 mM D-
glucose, 11.9 mM NaHCO3 and 0.21 mM Na2HPO4. CFTS was also
mixed with ACD (9 volumes of CFTS with 1 volume of ACD) and 2.5 μM
of PGE1 in order to produce Tyrode's-ACD-PGE1 (TAP) buffer. HEPES-
buffered Tyrode's solution contained 20 mM 2-[4-(2-hydroxyethyl)pi-
perazin-1-yl]ethanesulfonic acid (HEPES), 134 mM NaCl, 2.92 mM KCl,
12 mM NaHCO3, 0.34 mM Na2HPO4 and 1 mM MgCl2 with the pH
adjusted to 7.4.
2.4. Immunohistochemistry
Mice were terminally anaesthetised with urethane, lungs were then
collapsed before rapid tracheal cannulation and inflation of lungs with
0.5 ml OCT. The heart was then immediately removed to stop circu-
lation and lungs excised, cut in half laterally, and snap frozen in OCT on
a liquid nitrogen-cooled metal heat sink.
Samples were stored at −80 °C, then cryosectioned at 10 μm and
air-dried overnight. After fixation (4% vol/vol paraformaldehyde in
PBS, 15 min), peroxidase blockade was carried out with 3% vol/vol
H2O2 in ethanol for 10 min, and blockade of non-specific binding was
obtained with 1% w/vol BSA in PBS (also used as a diluent for other
reagents) used for 10 min. Samples were then incubated with either
biotinylated rat anti-CD41 antibody (MWReg30 clone, Abcam), rabbit
anti-CD42b antibody (SP219 clone, Abcam) or a rabbit anti-neutrophil
elastase antibody (Polyclonal ab68672, Abcam) (See Supplementary
Table 1 for full details of antibody reagents used). After 2 h, slides were
washed with PBS, then incubated for 1 h with avidin-biotinylated HRP
complex (for staining biotinylated primary, PK-7200, Vector labora-
tories), or biotinylated anti-rabbit IgG (BA-1000, 1 in 200, Vector la-
boratories), followed by a further wash and staining with avidin-bio-
tinylated HRP complex for 1 h (for staining unconjugated primary
antibodies). Along with the imaging reported in the Figures we stained
control samples where primary antibodies were not added to confirm
that any staining included in the quantification was not a result of non-
specific or off-target binding of reporter antibodies or probes.
Thresholds were set on these images during analysis so that any non-
target signal would be excluded. Examples of specificity controls have
been added to the data supplement (Supplementary Fig. 1). Slides were
washed with PBS again, developed with DAB, counterstained with
haematoxylin, mounted and coverslipped.
CD41 and neutrophil elastase were also visualised simultaneously
by staining with rat anti-CD41 antibody (MWReg30 clone, Abcam) and
rabbit anti-neutrophil elastase antibodies (polyclonal ab68672,
Abcam), washing with PBS, then incubation with low cross-reactivity
AlexaFluor594-conjugated anti-rat IgG and AlexaFluor488-conjugated
anti-rabbit IgG (1in500, both Thermo Fisher Scientific), with nuclei
counterstained with Hoechst 33258 (Sigma Aldrich).
2.5. Image capture and analysis
Bright field images (six 447 × 596 μm fields from every section)
were captured using a 20× objective on a Leica DM 2000 upright
microscope.
Using ImageJ with the colour deconvolution vectors plugin (from G.
Landini, University of Birmingham, UK), DAB and haematoxylin stains
were deconvoluted from RGB images as described elsewhere (Ruifrok &
Johnston, 2001). Positivity thresholds were set on DAB signal, and
platelets (CD41+,> 1.45μm2) were counted or neutrophil elastase
coverage was quantified using the ImageJ particle analyzer.
Separate blinded analyses were also conducted on the same mi-
croscope using a 63× objective to capture 50 image fields of
189 × 142 μm from the respiratory portion of the lung from each
mouse in order to enable the visualisation of platelets which appeared
outside of blood in the bronchoalveolar space. These extravascular
platelets were spatially dis-associated from blood vessels and were
manually counted by an independent observer.
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Whole lung sections double stained for neutrophil elastase and
CD41 using immunofluorescence were also imaged using the InCell
Analyzer 6000 with hardware and software autofocus for tiled acqui-
sition. Images were then thresholded, colour channels combined, and
tiles stitched as described elsewhere (Preibisch, Saalfeld, & Tomancak,
2009), to quantify bronchial lumen platelets (CD41+, inside lumen of
intact epithelium of bronchiole). CD41+ objects with proplatelet-like
morphology were identified by size and morphology (area > 55 μm2
and circularity< 0.5) and CD41+ cells (nuclei surrounded by CD41
positivity, megakaryocytes and precursors) were also counted.
2.6. Blood microsampling
Conscious mice were warmed to 37 °C for 10 min in a surgical re-
covery chamber. A 1–2 mm cut was made across a lateral tail vein and
blood was collected using a micropipette tip, and dispensed into stro-
matol for counting platelets, Turk's solution for counting leukocytes,
and used to make a smear for leukocyte differential counts with Kwik-
Diff stain.
2.7. Platelet radiolabelling
Blood for isolation of platelets was collected by cardiac puncture
from donor mice under anaesthesia into 100 μl ACD, and platelet rich
plasma was separated by centrifugation (3 min at 300 rcf, PRP re-
moved, 400 μl TAP buffer added, 3 min at 300 rcf, further PRP re-
moved, with red cells sedimented out with 2 min at 200 rcf). Platelets
were then separated from plasma (7 min at 1500 rcf), and resuspended
in 600 μl TAP buffer per 4 donor mice at a mean concentration of
6 ± 1 × 108 platelets/ml. The platelet suspension was then added to a
5:1 mixture of 1.8 MBq of 111InCl3 in sterile 0.9% w/vol saline
(Mallinckrodt) and 90 mM tropolone in HEPES-buffered Tyrode's so-
lution, and allowed to label for 10 min at room temperature. The pla-
telet suspension was centrifuged again and resuspended in 960 ml CFTS
for immediate intravenous infusion of 200 μl per mouse (mean labelling
efficiency: 62 ± 5%, 2.5 ± 0.5 × 108 labelled platelets per mouse).
Platelets were allowed to equilibrate in the mouse for at least 1 h before
beginning measurements.
2.8. Non-invasive recordings of thoracic platelet content
We utilised a previously described non-invasive method for mea-
suring continuous platelet recruitment into the thoracic region (Page
et al., 1982) that has been used for measuring lung platelet recruitment
into the lungs of guinea-pigs following LPS inhalation (Beijer et al.,
1987) or following intravenous LPS infusion in rats (Itoh et al., 1996).
This method has more recently been adapted for use in mice (Tymvios
et al., 2008). Thus, a SPEAR probe, calibrated to detect photon energies
from decay of Indium-111, was placed over the thorax and collimated
with 6 mm lead sheeting to maximise detection of platelet associated
radioactivity in the thorax and used to measure increases in platelet
recruitment in the pulmonary circulation following intravenous ad-
ministration of 4 mg/kg ADP, relative to background signal from
resting platelet associated radioactivity in the pulmonary circulation.
The presence of viable, circulating radiolabelled platelets 48 h after
transfusions was also confirmed by positive responses to i.v. adminis-
tration of ADP and measurements of platelet vs. plasma associated
radiolabel content. Repeated measurements in the same mouse over
hours and days were made possible using a cradle which positioned the
thorax of the mouse in a fixed position under the lead collimated SPEAR
gamma detector relative to a tooth bar on the isoflurane mask used to
maintain general anaesthesia. Means of thoracic radioactivity over
5 min periods were taken and the data were normalised to baseline
(pre-intranasal dosing with PBS or LPS).
2.9. Biodistribution of radiolabelled platelets in organs, blood and BAL
Mice transfused with radiolabelled platelets were terminally an-
aesthetised with urethane and whole blood collected by cardiac punc-
ture with 100 μl rapidly decanted for gamma counting. BAL fluid (3×
washes of 0.5 ml PBS), and lung, liver and spleens were also collected.
The percentage of the injected dose of radioactivity in whole blood
(100 μl), lungs, liver, spleen and BAL (800 μl, divided into cell pellet
and supernatant by centrifugation at 1500 rcf for 7 min) was measured
by gamma counting of samples and 1% injected dose controls using a
Wallac Compugamma 1282 system. Using a similar method to those
employed by others (Andonegui et al., 2005; Looney et al., 2009),
platelet recruitment from blood to organs was quantified by dividing
the quantity of radiolabel detected in whole, non-perfused organs by
the quantity of signal remaining in blood.
Inflammatory responses were confirmed by counting BAL leuko-
cytes using total cell counts and differential counts of Kwik-Diff stained
cytospin preparations.
2.10. Statistics
Data are presented as means± standard error and graphed and
analysed using GraphPad Prism 7.0. Group comparisons were made
using unpaired or paired t-tests, or 2-way ANOVA or ANCOVA with
single or repeated measures, and baseline values fit as covariates where
appropriate, followed by Holm's test for within-time point effects fol-
lowing LPS inhalation. Data were log transformed as required and
P < .05 was used as the threshold for statistical significance.
3. Results
3.1. LPS inhalation via intranasal administration results in increased
platelet recruitment to lungs
Mice were administered LPS or PBS intranasally, and blood and
lungs were collected 4 h and 48 h afterwards for immunohistochemical
analysis of platelets (Fig. 1A & B). In separate experiments, mice sub-
jected to this protocol were transfused with 111In-labelled platelets
detected non-invasively using a gamma radiation probe. 48 h after LPS
exposure, a time point when lung platelet recruitment was reported to
occur in a previous study (Ortiz-Muñoz et al., 2014), increases in both
lung platelet staining (Fig. 1C), and lung radiolabelled platelet re-
cruitment were detected (Fig. 1E).
3.2. LPS inhalation via intranasal administration causes an initial
temporary thrombocytopenia
Intranasal LPS administration initially elicited a fall in platelet
counts in the peripheral circulation, as measured by serial blood mi-
crosampling (Fig. 1D), and the quantity of radiolabelled platelets re-
maining in blood at 4 h after intranasal challenge (Fig. 1E). By 48 h
following intranasal challenge, there was no significant difference in
blood platelet counts (Fig. 1D) or in the retention of radiolabelled
platelets in blood between LPS treated mice and PBS controls (Fig. 1F),
providing evidence that increases in lung platelet staining were not
because of increased circulating platelet counts, and increases in the
lung:blood ratio were unlikely due to decreases in blood platelet re-
tention.
3.3. LPS inhalation via intranasal administration causes a temporary
decrease in radiolabelled platelet content in the thoracic region
Given that histological methods require cohorts of mice to be sa-
crificed at various time points to allow microscopical analysis of tissue
slices, and accumulation of radiolabelled platelets in organs via gamma
counting requires terminal removal of blood and organs, we attempted
S.J. Cleary, et al. Journal of Pharmacological and Toxicological Methods 102 (2020) 106660
3
to use a non-invasive technique, previously used to measure thrombo-
embolic responses in mice (Tymvios et al., 2008), to measure in-
trathoracic platelet accumulation in individual mice and therefore re-
duce animal use. This technique required the placement of a gamma
probe above the thoracic cavity of anaesthetised mice to record 111In-
labelled platelet accumulation via a spectrometer recording onto a
computer (Fig. 2A). Thus, an increase in platelet accumulation in the
thorax can be observed after the intravenous administration of ADP
(Fig. 2B & 2C). Conversely, the intravenous administration of LPS re-
vealed no immediate impact on platelet accumulation into the thoracic
region of terminally anaesthetised mice (Fig. 2D). Furthermore, mice
administered intranasal LPS had decreased thoracic radioactivity
compared to PBS controls at 4 h after challenge, correlating with the
decrease in blood platelet signal at 4 h after LPS inhalation (Cleary
et al., 2019), but no effect of LPS inhalation on thoracic radiolabelled
platelet content was measured at 24 or 48 h after LPS inhalation
(Fig. 2E). Normalising data from LPS-treated mice to that from PBS
vehicle controls to account for anticipated normal platelet lifespan in
the circulation, and then to correct for the estimated actual content of
radiolabelled platelets in blood measured at +4 and + 48 h from in-
tranasal challenge, suggested that the LPS-induced decrease in thoracic
signal was smaller than the effect of LPS on reducing blood platelet
counts (Supplementary Fig. 2A-C). This difference is suggestive that
non-invasive measurements of the lung platelet recruitment response
may be possible with the use of more sophisticated methods in-
corporating measurements of blood radiolabelled platelet content,
blood volume and 3D scanning to enable focus on the pulmonary vas-
culature.
Fig. 1. LPS inhalation causes platelet recruitment to
the lungs. (A) Mice were administered PBS or LPS
intransally, and lungs harvested at 4 h and 48 h for
immunohistochemical analysis and enumeration of
gamma-radiation counts. In some experiments, mice
were administered 111In-labelled platelets in-
travenously 1 h before LPS. (B) Platelets were en-
umerated with ImageJ using colour deconvolution
and particle analysis. Original RGB colour images
with CD41 staining in brown and haematoxylin
staining in blue were deconvoluted to split the colour
channels corresponding to DAB staining in a separate
greyscale image. An intensity threshold was then set
on the greyscale image to define areas of positivity.
Particle analysis was then used to count platelet
sized objects in the lungs (C), and separately, platelet
enumeration was in peripheral blood of same groups
of mice (D). 111In-labelled platelet radioactivity of
the lungs (E). % of injected 111In-labelled platelet
radioactivity remaining in the blood (F). Data is
mean ± standard error. Immunohistochemistry
conducted on PBS groups n = 4, LPS groups n = 8.
Radiolabelled platelet data conducted with n = 6
(4 h), n = 9 (48 h), 2-way ANOVA with Holm's test
for LPS effect within time points, * = P < .05,
** = P < .01, *** = P < .001 as indicated. Scale
bar = 20 μm. (For interpretation of the references to
colour in this figure legend, the reader is referred to
the web version of this article.)
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3.4. LPS inhalation via intranasal administration increases the content of
radiolabelled platelets in liver and spleen
The liver and the spleen are major sites of platelet clearance from
the circulation (Kaplan & Saba, 1978). We therefore investigated
whether the peripheral thrombocytopaenia recorded 4 h after LPS ex-
posure was due to the accumulation of platelets into these organs and
we observed increases in liver and spleen platelet recruitment asso-
ciated with the initial thrombocytopenia at this time point (Fig. 3A &
3B).
3.5. LPS inhalation via intranasal administration causes diapedesis of
platelets into lung airspaces
The quantity of radiolabelled platelets was measured in BAL fluid
cell pellets and supernatant. No effect of LPS was detected 4 h after LPS
inhalation, but by 48 h after intranasal challenge with LPS, the BAL
radiolabel content in mice was increased (Fig. 4A). A readout of 0.01%
of injected dose corresponds to approximately 27,500 platelets per ml
of BAL fluid.
Sections of lung from mice exposed to LPS or PBS controls were also
stained for immunofluorescent labelling of CD41 (Fig. 4B) in order to
visualise platelets in airspaces and overcome the problem of false po-
sitive staining found around respiratory epithelium when using DAB
reporters. A survey of small intact airways revealed CD41+ platelets
associated with cells, some of which were neutrophil elastase positive,
and others were not (Fig. 4B). Quantitative analysis revealed a small,
yet significant accumulation of platelets in the bronchial lumen 48 h
after LPS administration (Fig. 4C). However, it should be noted that LPS
administration induces significant inflammation around small blood
vessels and alveolar-capillary units more distal in the lung parenchyma.
Therefore, images of fields of alveolar-capillary networks also stained
for platelets. These sections were stained for the platelet antigen
CD42b, which was found to provide a stronger staining signal than the
CD41 method (Cleary et al., 2019). Sections were captured with a high-
power 63× objective and used for manual counting of platelets that
were not visibly within alveolar capillaries or pulmonary blood vessels
and so appeared extravascular in the alveolar airspaces (Fig. 4D). LPS
inhalation caused a significant increase in the number of extravascular
platelets (PBS vs. LPS: 55 ± 5 plts per mm2 vs. 252 ± 65 plts per
mm2. Fig. 4E).
Fig. 2. Use of Gamma-radiation probe to detect lung
platelet accumulation. Mice transfused with 111In-
labelled platelets were anaesthetised using iso-
flurane, with repeated recordings made over the
same region of thorax by clamping a gamma detector
at a fixed position relative to a tooth bar and custom
cradle attached to the isoflurane mask. Signal from
the gamma detector was de-convoluted using a
UCS30 spectrophotometer and data logged on a
computer running USX software (A). Responses to
i.v. injections of 4 mg/kg ADP in mice infused 48 h
previously with 111In-labelled platelets (B). Analysis
of pre and post ADP signal showing maximal per-
centage increases in time periods relative to the
baseline (C). Single trace showing acute response to
intranasal LPS (5 mg/kg) inhalation in a terminally
anaesthetised mouse (D). Measurements of thoracic
radioactivity were made at 0, 2, 4, 24, and 48 h after
intranasal challenge with LPS, data shown as %
change from time 0 h (E). Data are mean ±
standard error where error bars are shown. ADP
data: n = 6, comparison is paired t-test. LPS data
n = 5, two way ANCOVA with baseline values fit as
covariates, with repeated measures and Holm's test
for effects of LPS inhalation within time points.
* = P < .05, ** = P < .01.
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3.6. LPS inhalation via intranasal administration increases the quantity of
CD41+ events with proplatelet or megakaryocyte-like morphology in the
lungs
Recent estimates suggest that around half of blood platelets origi-
nate from megakaryocyte fragmentation in the pulmonary circulation
in healthy mice (Lefrançais et al., 2017). However, previously reported
methods did not allow for discrimination of megakaryocytes from
proplatelets or platelet aggregates in inflamed lungs (Ortiz-Muñoz
et al., 2014). Immunofluorescence and tiled acquisition and stitching
allowed for improved identification of CD41+ events with proplatelet
morphology (Fig. 5A) and CD41+ cells with large nuclei consistent
with the appearance of megakaryocytes (Fig. 5B), with both popula-
tions increased in number in lungs following LPS inhalation (Fig. 5C,
D).
4. Discussion
We present here evidence that LPS can induce platelet recruitment
into the lungs and airspaces which we have detected with im-
munohistochemistry and by monitoring the recruitment of radi-
olabelled platelets following an initial decrease in platelet counts in the
peripheral circulation.
Our initial aim was to measure increases in the quantity of lung
platelets by detecting an increase in thoracic radioactivity as previously
achieved in guinea pigs following exposure to aerosolised LPS (Beijer
et al., 1987). Measurement of lung platelet recruitment using this
method was likely confounded by a decrease in blood platelets more
closely temporally associated with increases in liver and spleen platelet
content rather than with lung platelet recruitment, and possibly also by
changes in the blood content of either the lung or of the systemic
vasculature beneath the detector probe. As this relatively simple pla-
telet monitoring method was not successful in measuring lung platelet
recruitment, we would recommend that future approaches employ
blood microsampling (to monitor changes in the radiolabelled platelet
content of blood over time), 3-dimensional single-photon emission
computed tomography imaging methods (to permit exclusive focus on
the pulmonary vasculature), and co-administration of differentially la-
belled red blood cells to control for regional alterations in blood supply
(Doerschuk et al., 1990). However, previously in this model we have
measured flux of non-adhesive platelets in LPS-challenged lung mi-
crovasculature and in PBS controls, and found no difference, suggestive
of a lack of LPS-induced alteration in pulmonary blood flow (Cleary
et al., 2019). These approaches may enable repeated non-invasive
measurements of lung radiolabelled platelet recruitment in mice and
combined with fate-tracking imaging methods might provide answers
to the question of whether platelets recruited to the lung come from the
blood pool or are released secondary to their retention in spleen or
liver. The development of real-time imaging techniques to measure
platelet recruitment would allow these advances to be made with the
use of fewer animals and without use of procedures in conscious ani-
mals, in line with European and UK legislation requiring animal pro-
cedures to be conducted with consideration to reduction, refinement
and replacement.
The successful quantification of immunostained lung platelets and
blood platelets using microsampling shows ready promise for use of
these methods in investigation of the molecular and cellular basis of
platelet responses in response to inflammatory and pathogenic stimuli
(Cleary et al., 2019).
Detection of increased platelet content in BAL fluid, within the
lumen of bronchioles, and in extravascular alveolar spaces are con-
sistent with previous reports of LPS-induced diapedesis of platelets into
lung tissue (Ortiz-Muñoz et al., 2014), and following bacterial infection
of the lung (Amison et al., 2018). Visualisation of platelet diapedesis
using intravital microscopy, and platelet-specific knockout of adhesion
molecules are required to provide further evidence for these phe-
nomena reflecting directed platelet migration across the endothelial
and epithelial barriers, as previously shown in lungs of allergic mice
following allergen challenge (Pitchford et al., 2008).
Increases in lung content of CD41+ nucleate cells and anucleate
proplatelets following LPS inhalation are suggestive of effects of LPS on
lung thrombopoiesis, although dynamic lung imaging and measure-
ments of megakaryocytes and proplatelets in blood and bone marrow
are required to determine to what extent these images are due to al-
terations in lung-derived megakaryocyte precursors or bone marrow
release, pulmonary trapping or retention of megakaryoctyes and pro-
platelets (Lefrançais et al., 2017).
In summary, we have found that exposure of mice to inhaled LPS
caused temporally distinct increased lung, liver and spleen platelet re-
cruitment while decreasing blood platelet content, and hope that the
methods described in the present study for measuring these responses
will help with future experimentation designed to increase our under-
standing of the involvement of platelets in lung inflammation and host
defence.
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Fig. 3. LPS inhalation causes increases in liver and
spleen platelet recruitment. Mice were administered
111In-labelled platelets intravenously, then PBS or
LPS intranasally. Livers, spleens, and blood were
collected at 4 and 48 h after intranasal challenge.
The % 111In-labelled platelet radioactivity of the
liver or spleen was divided by the % of injected
111In-labelled platelet radioactivity remaining in the
blood to measure (A) liver platelet recruitment, (B)
spleen platelet recruitment. Mean ± standard error,
4 h time point: n = 6, 48 h time point: n = 9, 2-way
ANOVA with Holm's test for LPS effect within time
points, * = P < .05, *** = P < .001.
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Fig. 4. Evidence for platelet migration into airspaces following LPS inhalation. Mice were administered PBS or LPS intranasally, and lungs harvested at 48 h for
immunohistochemical analysis. In some experiments, mice were administered 111In-labelled platelets intravenously 1 h before LPS and BAL fluid was collected at 4
and 48 h after LPS exposure and 111In-platelet content quantified. (A) 111In-platelet content in BAL fluid. (B) Airways (dashed line) were identified in lung sections
stained for CD41 (red), neutrophil elastase (green) and nuclei (blue) (top panels). Bottom panels: CD41 stain only. Airway lumen platelets are highlighted with
arrowheads. Scale bar: 20 μm. (C) The number of CD41+ platelets within airways was quantified and expressed as number per total area of sections surveyed. (D)
Lung sections immunostained for CD42b (brown) with haematoxylin counterstain (blue). Platelets appearing extravascularly with intra-alveolar neutrophils (black
arrowhead) and alone (black arrow) inside alveolar airspaces (dotted lines) are shown.(E) Quantification of CD42b + platelets detected in alveolar airspaces. Data
are mean ± standard error. Radiolabelled platelet data conducted with n = 6 (4 h), n = 9 (48 h), 2-way ANOVA with Holm's test for LPS effect within time points.
Immunohistochemistry data with conducted with PBS: n = 6 and LPS: n= 7 (CD41 data), or PBS: n = 4, LPS: n = 8 (CD42b data). Comparisons are Mann-Whitney
test. * = P < .05, ** = P < .01. Scale bars = 20 μm. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of
this article.)
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